Cancer Research Audrey Hepburn EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shah, A. H.
Right arrow Articles by Lee, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, A. H.
Right arrow Articles by Lee, C.
[Cancer Research 62, 7135-7138, December 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Suppression of Tumor Metastasis by Blockade of Transforming Growth Factor ß Signaling in Bone Marrow Cells through a Retroviral-mediated Gene Therapy in Mice1

Ali H. Shah, William B. Tabayoyong, Shilajit D. Kundu, Seong-Jin Kim, Luk Van Parijs, Victoria C. Liu, Eugene Kwon, Norman M. Greenberg and Chung Lee2

Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611 [A. H. S., W. B. T., S. D. K., V. C. L., C. L.]; Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892 [S-J. K.]; Department of Biology, Massachusetts Institute of Technology, Cambridge Massachusetts 02139 [L. V. P.]; Department of Urology, Mayo Clinic, Rochester, Minnesota 55905 [E. K.]; and Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030 [N. M. G.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Transforming growth factor B (TGF-ß) is a potent immunosuppressive cytokine that is frequently associated with mechanisms of tumor escape from immunosurveillance. We report that transplantation of murine bone marrow (BM) expressing a dominant-negative TGF-ß type II receptor (TßRIIDN) leads to the generation of mature leukocytes capable of a potent antitumor response in vivo. Hematopoietic precursors in murine BM from donor mice were rendered insensitive to TGF-ß via retroviral expression of the TßRIIDN construct and were transplanted in C57BL/6 mice before tumor challenge. After i.v. administration of 5 x 105 B16-F10 murine melanoma cells into TßRIIDN-BM transplanted recipients, survival of challenged mice at 45 days was 70% (7 of 10) versus 0% (0 of 10) for vector-control treated mice, and surviving TßRIIDN-BM mice showed a virtual absence of metastatic lesions in the lung. We also investigated the utility of the TGF-ß-targeted approach in a mouse metastatic model of prostate cancer, TRAMP-C2. Treatment of male C57BL/6 mice with TßRIIDN-BM resulted in the survival of 80% (4 of 5) of recipients versus 0% (0 of 5) in green fluorescent protein-BM recipients or wild-type controls. Cytolytic T-cell assays indicate that a specific T-cell response against B16-F10 cells was generated in the TßRIIDN-BM-treated mice, suggesting that a gene therapy approach to inducing TGF-ß insensitivity in transplanted BM cells may be a potent anticancer therapy.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Tumor immunotherapies to date have focused largely on the priming of immune responses to fight cancer, with mixed results and generally poor efficacy. In addition to immune stimulation, the issue of overcoming active immune suppression must also be considered when developing an immune-based strategy for cancer therapy (1 , 2) , particularly with regard to secreted soluble factors that are known to down-regulate immune function and antitumor response. Most significant of these is the pleiotropic cytokine TGF-ß,3 (3) which has previously been shown to act in a critical inhibitory fashion on most cells of the immune system and is secreted by a wide variety of tumor types, many of which down-regulate expression of their own TGF-ß receptors (4, 5, 6, 7) to circumvent the growth-inhibitory activity of TGF-ß signaling. Tumor-secreted TGF-ß is capable of inhibiting the response of tumor-specific lymphocytes (8) , including sites of metastatic tumor growth (9) . The potency of TGF-ß as an immunosuppressive cytokine makes it an attractive target as an anticancer therapy, because, as it has been suggested, a breakdown of self-tolerance mechanisms in the periphery may be a critical element in fighting nonimmunogenic tumors (10) . We hypothesized that an immunotherapy strategy that specifically blocks TGF-ß signaling in immune cells, regardless of tumor location or tumor microenvironment, could be highly successful in mediating an antitumor response.

We chose to use a retroviral-mediated gene therapy approach abrogating TGF-ß signaling in hematopoietic stem cells in the BM, because this approach has been shown recently to be a successful protocol in the delivery of long-term transgene expression in immune effector cells (11) . Here, we show that abrogation of TGF-ß signaling in the immune compartment via retrovirus-mediated expression of a TßRIIDN in transplanted BM-derived stem cells elicits potent antitumor activity when treated animals are challenged i.v. with highly tumorigenic melanoma or prostate cancer cells.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Mice.
Male C57BL/6 mice, 6–8 weeks of age, were obtained from Jackson Labs (Bar Harbor, ME) and maintained in pathogen-free facilities at the Center for Comparative Medicine at Northwestern University Feinberg School of Medicine in accordance with established guidelines of the Animal Care and Use Committee of Northwestern University.

BM Isolation and Culture.
Donor mice were inhalation-anesthetized and were given injections i.p. of 5 mg of 5-fluorouracil (Sigma, St. Louis, MO). Five days later, mice were sacrificed by cervical dislocation and hind femora and tibiae were isolated and cleaned of tissue before being flushed aseptically with DMEM plus 10% fetal bovine serum (DMEM-10) using 26-gauge needles. The RBCs in the marrow preparation were then lysed using a hypotonic ammonium chloride solution (PharMingen, Becton-Dickinson, San Diego, CA). The processed marrow was resuspended in fresh DMEM-10 supplemented with 100 ng/ml stem cell factor, 50 ng/ml IL-6, and 20 ng/ml IL-3 (R&D, Minneapolis, MN) at 1–2 x 106 cells/ml, and were incubated at 37°C/5% CO2.

Construction of TßRIIDN-GFP Retroviral Vector.
The procedure for the construction of the TßRIIDN viral vector has been described earlier (12) . Briefly, a truncated sequence of the human TGF-ß type II receptor was cloned into a mouse stem-cell virus-based bicistronic retroviral vector coexpressing GFP under the control of the 5' long terminal repeat viral promoter. The truncated receptor contained both the extracellular domain and the transmembrane domain but lacked the cytoplasmic kinase domain. The control empty vector was designated as the GFP vector.

Production of Infectious TßRIIDN-GFP Retrovirus.
Pantropic GP293 retroviral packaging cells (Clontech, San Diego, CA) were seeded at a density of 2.5 x 106 cells in collagen-I-coated T-25 flasks (BIOCOAT; BD Biosciences, Mountain View, CA) 24 h before plasmid transfection in antibiotic-free DMEM-10, such that the cells were ~70–90% confluent at the time of transfection, at which point the cells were rinsed with PBS to remove residual serum. A mixture of 2 µg of retroviral plasmid and 2 µg of VSV-G envelope plasmid were cotransfected in serum-free DMEM using LipofectAMINE-Plus (Invitrogen, Gaithersburg, MD) according to the manufacturer’s protocols with the following modifications. Cells were transfected for 12 h followed by the addition of an equivalent volume of DMEM-20 and reincubation for an additional 12 h. After 24 h of total transfection time, the supernatant was aspirated, the cells were rinsed gently in PBS, and 3 ml of fresh DMEM-10 was added to each flask. After 24 h, virus-containing supernatant was collected and used to infect target cells.

Western Blotting for SMAD-2 Phosphorylation.
The infected primary mouse BM cells were treated with or without 10 ng/ml TGF-ß1 for 30 min in culture to test the functionality of the TGFß signaling pathway (12) . Proteins in the cell lysate were subjected to electrophoresis (Novex/10% acrylamide gel) and blotted onto a polyvinylidene difluoride membrane. Blots were probed using monoclonal antibody against phosphorylated SMAD-2. Blots were stripped and reprobed with antibodies against SMAD-2 and then glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Retroviral Infection and Transplantation of Murine BM.
Cultured murine BM cells were infected on days 2 and 3 postisolation via spin infection as follows: an aliquot of 1 ml of viral supernatant was added to each well of a 24-well plate containing BM cells in the presence of a minimum concentration of 4 µg/ml Polybrene (Sigma), spun at 1000 x g for 90 min, and supplemented with 1 ml of fresh cytokine-supplemented DMEM-10. On day 4–5, cells were examined for GFP expression, washed two times in PBS, and injected into the lateral warmed tail veins of irradiated (1200 rads) recipient C57BL/6 mice. Transplanted mice were maintained on sulfamethoxazole/trimethoprim for a minimum of 2 weeks to prevent opportunistic infection.

i.v. Inoculation of Tumor Cells into Mice after BM Transplant.
C57Bl/6 mice receiving TßRIIDN, GFP, or nontransduced BM transplants were challenged i.v. with 5 x 105 B16-F10 cells (n = 10 mice/group) or TRAMP-C2 cells (n = 5 animals/group) 2 months after transplant. The B16-F10-challenged mice were monitored for morbidity and mortality for 6 weeks, and the TRAMP-C2-challenged mice were monitored for 8 weeks. At the conclusion of each experiment, all of the animals were inspected for the presence of metastases. Statistical analysis was conducted on a Kaplan-Meier survival curve, using the log-rank test (13) .


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Functional Status of TGF-ß Signaling in Transfected BM.
Transfection efficiency into primary BM cells using the above approach was consistently greater than 90% as assayed by GFP expression (12) . Results of the functional analysis of these transfected BM cells have been reported earlier (12) . Briefly, when the TßRIIDN BM cells were treated with 10 ng/ml TGF-ß1 in culture, the expression of the dominant negative receptor resulted in an absence of SMAD-2 phosphorylation. SMAD-2 phosphorylation was observed in similarly treated mock-infected cells or cells infected with the control vector expressing GFP alone (12) . Furthermore, at 6-months posttransplant, the results of flow cytometry data indicated that there was no significant reduction of GFP expression in BM cells of either TßRIIDN- or GFP-transduced mice (12) .

Increased Survival and Decreased Metastases in TßRIIDN-BM-treated Mice.
C57BL/6 mice receiving TßRIIDN, GFP, or nontransduced BM transplants (n = 10 mice/group) were challenged with 5 x 105 B16-F10 cells i.v. and monitored for morbidity and mortality for a period of ~6 weeks. Whereas 100% of wild-type and GFP transplant recipients were dead by 22 days postchallenge, there was no mortality observed in the TßRIIDN-BM recipient group (Fig. 1A)Citation by this time. The TßRIIDN-BM control group was monitored for a total period of 45 days postchallenge, at which point surviving (7 of 10) mice were sacrificed and their lung tissue removed for macroscopic examination to determine whether metastatic lesions comparable with those observed in the wild type-BM and GFP-BM control groups were present. As shown in Fig. 1BCitation , the lung tissue of untreated control mice was characterized at the time of death by numerous black melanoma metastases throughout the tissue. However, the TßRIIDN-BM-treated group had fewer metastatic lesions in the lungs of nonsurviving mice and virtually no discernable lesions in the lungs of mice surviving throughout the duration of the experiment. These results strongly suggest that mice transplanted with BM with targeted blockade of TGF-ß signaling generate potent antitumor immunity in C57BL/6 mice challenged with highly metastatic, nonimmunogenic tumor cells.



View larger version (65K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Antitumor capacity of mice receiving transplant of TßRIIDN-BM. A, Kaplan-Meier survival curve of C57BL/6 mice challenged with 5 x 105 B16-F10 melanoma cells via tail vein injection after transplantation with 2–4 x 106 syngeneic BM cells transduced with TßRIIDN-expressing retrovirus, GFP control virus, or uninfected wild-type BM cells (n = 10/group; P < 0.01 by the log-rank test for the TßRIIDN group versus GFP or control group; Ref. 13 ). B, lungs of mice 3 weeks post-tumor challenge from TßRIIDN-transplanted mice (left) or GFP control mice (right). The GFP control lung is covered with black, melanin-producing tumor cells. The lung in the TßRIIDN-treated group is devoid of any tumor.

 
To determine the efficacy of the TßRIIDN-BM treatment on metastatic tumor formation in a model of prostate cancer, we subsequently challenged TßRIIDN-BM treated male C57BL/6 mice with i.v. administration of 5 x 105 TRAMP-C2 cells and monitored the mice similarly as described above. At 3 weeks postchallenge, macroscopic tumor formation was difficult to detect in either the treated or untreated controls, indicating that the TRAMP-C2 tumor cells were not as aggressive in their formation of metastatic lung foci as were the B16-F10 tumor cells. However, on further examination of histological specimens of mice sacrificed at 21 days post tumor challenge, micrometastatic lesions were already visible in the GFP group but not in the TßRIIDN group (data not shown). A second group of mice was tumor challenged and monitored for a period of 8 weeks, by which point the survival of the wild-type and GFP control mice was 0% (0 of 5, each group by week 7; Fig. 2ACitation ), whereas the survival of the TßRIIDN-BM treated cohort was 100% (5 of 5). By week 9, one animal in the TßRIIDN-BM group died, leaving the overall survival rate of 80% (4 of 5) for this group. Results of statistical analysis, using the log-rank test, indicated P < 0.05 between the TßRIIDN-BM and the other two control groups. Postmortem analysis of the untreated or vector-control-treated animals indicated a significant tumor burden evident in the lung tissue of each mouse (Fig. 2B)Citation , whereas the lungs of TßRIIDN mice remained metastases free. From these data, we conclude that targeting immune TGF-ß signaling with BM-directed retroviral therapy is an effective means of preventing metastatic prostate tumor growth in mice.



View larger version (64K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. TßRIIDN-BM-treated mice showing antitumor capacity against TRAMP-C2 mouse prostate cancer tumor challenge. 5 x 105 TRAMP-C2 prostate adenocarcinoma cells were injected via the tail vein into TßRIIDN-BM-treated mice, and the mice were monitored for morbidity and mortality. A, survival of wild-type (untreated), GFP, and TßRIIDN-transplanted mice post-tumor challenge (n = 5/group), expressed as the Kaplan-Meier curve. (P < 0.05 by the log-rank test for the TßRIIDN group versus the control or GFP group; Ref. 13 ). B, lung tissue from TßRIIDN-BM- and GFP-BM-treated mice at 6 weeks post-tumor challenge indicating metastatic tumor foci (arrows).

 
TßRIIDN Mice Generate Specific Antitumor CTLs in Vivo.
To determine whether the antitumor response generated by transplant of TßRIIDN-BM is tumor-specific, we collected splenocytes from TßRIIDN-BM- and GFP-BM-tumor-challenged mice at 3 weeks post-tumor challenge and assayed the ability of CTLs to lyse B16-F10 cells in vitro using a standard 51Cr release assay. Results from the CTL assay indicated a significant increase in tumor-specific lysis of melanoma cells in splenocytes from TßRIIDN-BM-transplanted mice compared with GFP control-treated counterparts (Fig. 3A)Citation , suggesting that the antitumor phenotype in TGF-ß signaling pathway-deficient mice is at least partially caused by CTL activity and not simply a result of broader, nonspecific immune stimulation of treated mice. Likewise, a 51Cr release assay performed on labeled TRAMP-C2 cells by splenocytes recovered from TßRIIDN-BM- and GFP-BM-transplanted mice (Fig. 3B)Citation indicate that tumor-specific cytolysis is generated by the retroviral blockade of TGF-ß signaling.



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Generation of tumor-specific killing in TßRIIDN-BM-transplanted mice. Splenocytes from tumor-challenged mice were collected and stimulated for 5 days with irradiated B16-F10 mouse melanoma cells (A) or with TRAMP-C2 mouse prostate carcinoma cells (B) before being cocultured with 51Cr-labeled targets at the indicated E:T ratios. Samples were analyzed in duplicate (A) or triplicate (B) wells.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
Results of the present study demonstrate that disruption of the TGF-ß signaling pathway in BM cells using a gene therapy approach confers an antitumor phenotype on treated mice. Targeting of TGF-ß-mediated immunosuppression has been used previously to show that the blockade of normal TGF-ß signaling pathways confers an antitumor effect in a variety of tumor models, either via modulation of tumor TGF-ß production in a tumor vaccine approach or via the systemic down-regulation of available TGF-ß cytokine in the serum, and has been used in a variety of tumor therapies to combat both primary and secondary tumor growth. Ex vivo transfer of an antisense TGF-ß construct into isolated tumor cells followed by reimplantation into the brain of rats with established gliomas has been shown to result in complete eradication of the tumors in vivo (14) , and a similar approach has been used successfully to confer immunogenicity to a prostate tumor model in the Dunning rat (15) . Systemic administration of anti-TGF-ß antibody and IL-2 shows a significant decrease in number and size of metastatic B16 tumor lesions (16) , suggesting that TGF-ß immunosuppression can be at least partially overcome by a general TGF-ß signal blockade. This latter approach, including similar approaches such as soluble TGF-ß type II receptor therapy (17) , although providing a rationale for a TGF-ß-targeted approach in cancer therapy, may be ultimately limited in its ability to mediate antitumor effects at sites in which the delivery of a soluble therapeutic agent may be insufficient to block TGF-ß present at high concentrations in tumor microenvironments.

In the present study, we demonstrated the therapeutic efficacy of targeting progenitors of leukocyte populations in the BM with retroviral particles that specifically blocked TGF-ß signaling by expressing a dominant negative TGF-ß type II receptor with a truncated cytoplasmic domain. The lack of formation of metastatic lesions in TßRIIDN-BM-treated mice after i.v. administration with highly metastatic B16-F10 cells emphasizes the importance of the TGF-ß signaling pathway to tumorigenicity in vivo, even in the case of tumor cells with aggressive growth properties and little natural immunogenicity. Likewise, the lack of metastatic lesion formation in TßRIIDN-BM-treated animals after a challenge with TRAMP-C2 cells, a murine model of prostate cancer, supports the idea that this antitumor approach is viable in a range of cancers of different tissue origins.

The potency of TGF-ß as an immunoregulatory cytokine that is critical for the maintenance of immune homeostasis also necessitates the careful application of perturbations in the TGF-ß signaling processes for cancer immunotherapy. The potential for the generation of widespread autoimmunity and inflammation, which is generated in the absence of functional TGF-ß pathways in immune cells (12) , makes it essential that the approach described here be maximized for its utility as an antitumor therapy but modified so as to minimize potential autoimmune side effects against host tissue. Mice that are deficient in TGF-ß1 cytokine display a massive auto-inflammatory phenotype and quickly succumb to systemic damage in a variety of tissues (18 , 19) , whereas other transgenic models, restricted to TGF-ß-signal abrogation in the immune compartment or single lineages including T (20) and B cells (21) , similarly result in dysregulation of immune function. The retroviral approach to therapeutic gene delivery can be enhanced by vectors that offer a regulatory mechanism to control expression of the transgene and/or survival of transgene-positive cells, whether through the use of on/off systems responsive to pharmacological agents (e.g., tetracycline) or through the use of suicide gene elements present in the integrated viral genome.

We submit that the results presented here represent a viable approach to the problem of tumor escape from immune surveillance using readily available retroviral gene transfer technology, and we suggest that this approach could potentially be coupled with other immunostimulatory protocols that generate tumor-specific lymphocyte responses but that, to date, have had only mixed results because of a lack of cytotoxic effector activity, particularly with regard to distant metastatic tumor foci, as a result of TGF-ß-mediated immunosuppression. The hematopoietic stem-cell gene therapy approach, already established as a viable means for the delivery of therapeutic genes to cells of the immune system, provides a legitimate and characterized target for TGF-ß signaling-directed therapy for a potentially wide variety of cancers.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by GrantDAMD17-99-1-9009 from the Department of Defense. Back

2 To whom requests for reprints should be addressed, at Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Tarry 16-733, Chicago, IL 60611. Phone: (312) 908-2004; Fax: (312) 503-2685; E-mail: c-lee7{at}northwestern.edu Back

3 The abbreviations used are: TGF-ß, transforming growth factor ß; GFP, green fluorescent protein; TßRIIDN, dominant negative type II TGF-ß receptor; BM, bone marrow; TRAMP, TGF-ß-targeted approach in a mouse metastatic model of prostate cancer; IL, interleukin. Back

Received 7/ 8/02. Accepted 10/31/02.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy[see comments]. J. Immunother., 20: 165-177, 1997.
  2. Shah A. H., Lee C. TGF-ß-based immunotherapy for cancer: breaching the tumor firewall. Prostate, 45: 167-172, 2000.[Medline]
  3. Letterio J. J., Roberts A. B. Regulation of immune responses by TGF-ß. Annu. Rev. Immunol., 16: 137-161, 1998.[Medline]
  4. Kim I. Y., Ahn H. J., Zelner D. J., Shaw J. W., Sensibar J. A., Kim J. H., Kato M., Lee C. Genetic change in transforming growth factor ß (TGF-ß) receptor type I gene correlates with insensitivity to TGF-ß1 in human prostate cancer cells. Cancer Res., 56: 44-48, 1996.[Abstract/Free Full Text]
  5. Guo Y., Jacobs S. C., Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-ß (TGF-ß1) type I and type II receptors in human prostate cancer. Int. J. Cancer, 71: 573-579, 1997.[Medline]
  6. Kim Y. S., Yi Y., Choi S. G., Kim S. J. Development of TGF-ß resistance during malignant progression. Arch. Pharm. Res. (Seoul), 22: 1-8, 1999.[Medline]
  7. Park K., Kim S. J., Bang Y. J., Park J. G., Kim N. K., Roberts A. B., Sporn M. B. Genetic changes in the transforming growth factor ß (TGF-ß) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-ß. Proc. Natl. Acad. Sci. USA, 91: 8772-8776, 1994.[Abstract/Free Full Text]
  8. Inge T. H., Hoover S. K., Susskind B. M., Barrett S. K., Bear H. D. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor ß1. Cancer Res., 52: 1386-1392, 1992.[Abstract/Free Full Text]
  9. Lee H. M., Timme T. L., Thompson T. C. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res., 60: 1927-1933, 2000.[Abstract/Free Full Text]
  10. Nanda N. K., Sercarz E. E. Induction of anti-self-immunity to cure cancer. Cell, 82: 13-17, 1995.[Medline]
  11. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J. L., Bousso P., Deist F. L., Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease[see comments]. Science (Wash. DC), 288: 669-672, 2000.[Abstract/Free Full Text]
  12. Shah A. H., Tabayoyong W. B., Kimm S. Y., Kim S.-J., van Paris L., Lee C. Reconstitution of lethally irradiated adult mice with dominant negative TGF-ß type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J. Immunol., 169: 3485-3491, 2002.[Abstract/Free Full Text]
  13. Freedman L. S. Tables of the number of patients required in clinical trials using the log rank test. Stat. Med., 1: 121-129, 1982.[Medline]
  14. Fakhrai H., Dorigo O., Shawler D. L., Lin H., Mercola D., Black K. L., Royston I., Sobol R. E. Eradication of established intracranial rat gliomas by transforming growth factor ß antisense gene therapy. Proc. Natl. Acad. Sci. USA, 93: 2909-2914, 1996.[Abstract/Free Full Text]
  15. Matthews E., Yang T., Janulis L., Goodwin S., Kundu S. D., Karpus W. J., Lee C. Down-regulation of TGF-ß1 production restores immunogenicity in prostate cancer cells. Br. J. Cancer, 83: 519-525, 2000.[Medline]
  16. Wojtowicz-Praga S., Verma U. N., Wakefield L., Esteban J. M., Hartmann D., Mazumder A., Verma U. M. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor ß antibody and interleukin-2[erratum appears in J. Immunother. Emph. Tumor Immunol., 19: 386, 1996]. J. Immunother. Emph. Tumor Immunol., 19: 169-175, 1996.[Medline]
  17. Won J., Kim H., Park E. J., Hong Y., Kim S. J., Yun Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor ß receptor therapy. Cancer Res., 59: 1273-1277, 1999.[Abstract/Free Full Text]
  18. Kulkarni A. B., Huh C. G., Becker D., Geiser A., Lyght M., Flanders K. C., Roberts A. B., Sporn M. B., Ward J. M., Karlsson S. Transforming growth factor ß1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA, 90: 770-774, 1993.[Abstract/Free Full Text]
  19. Shull M. M., Ormsby I., Kier A. B., Pawlowski S., Diebold R. J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D., Annunziata N., Doetschman T. Targeted disruption of the mouse transforming growth factor-ß1 gene results in multifocal inflammatory disease. Nature (Lond.), 359: 693-699, 1992.[Medline]
  20. Lucas P. J., Kim S. J., Melby S. J., Gress R. E. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor ß II receptor. J. Exp. Med., 191: 1187-1196, 2000.[Abstract/Free Full Text]
  21. Cazac B. B., Roes J. TGF-ß receptor controls B cell responsiveness and induction of IgA in vivo. Immunity, 13: 443-451, 2000.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
K. A. Shafer-Weaver, M. J. Anderson, K. Stagliano, A. Malyguine, N. M. Greenberg, and A. A. Hurwitz
Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells
J. Immunol., October 15, 2009; 183(8): 4848 - 4852.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Laje, D. Shang, W. Cao, M. Niiya, M. Endo, A. Radu, N. DeRogatis, F. Scheiflinger, P. W. Zoltick, A. W. Flake, et al.
Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy
Blood, March 5, 2009; 113(10): 2172 - 2180.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Zhang, B. E. Berndt, J.-J. Chen, and J. Y. Kao
Expression of a Soluble TGF-{beta} Receptor by Tumor Cells Enhances Dendritic Cell/Tumor Fusion Vaccine Efficacy
J. Immunol., September 1, 2008; 181(5): 3690 - 3697.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
B. A Teicher, J. M Yingling, and J. M McPherson
TGF{beta} Blockade as Anticancer Therapy
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 71 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
Y. Shintani, M. Maeda, N. Chaika, K. R. Johnson, and M. J. Wheelock
Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor Signaling
Am. J. Respir. Cell Mol. Biol., January 1, 2008; 38(1): 95 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Teicher
Transforming Growth Factor-{beta} and the Immune Response to Malignant Disease
Clin. Cancer Res., November 1, 2007; 13(21): 6247 - 6251.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. T. Lee, J. H. Hong, C. Kwak, J. Woo, V. Liu, C. Lee, and I. Y. Kim
Effect of Dominant Negative Transforming Growth Factor-{beta} Receptor Type II on Cytotoxic Activity of RAW 264.7, a Murine Macrophage Cell Line
Cancer Res., July 15, 2007; 67(14): 6717 - 6724.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Suzuki, S. Kim, H.-K. Cheung, M. J. Corbley, X. Zhang, L. Sun, F. Shan, J. Singh, W.-C. Lee, S. M. Albelda, et al.
A Novel Small-Molecule Inhibitor of Transforming Growth Factor {beta} Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection
Cancer Res., March 1, 2007; 67(5): 2351 - 2359.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Zhu, K. Fukada, H. Zhu, and N. Kyprianou
Prohibitin and Cofilin Are Intracellular Effectors of Transforming Growth Factor {beta} Signaling in Human Prostate Cancer Cells.
Cancer Res., September 1, 2006; 66(17): 8640 - 8647.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Q. Zhang, X. J. Yang, S. D. Kundu, M. Pins, B. Javonovic, R. Meyer, S.-J. Kim, N. M. Greenberg, T. Kuzel, R. Meagher, et al.
Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle.
Mol. Cancer Ther., July 1, 2006; 5(7): 1733 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Varghese, S. D. Rabkin, P. G. Nielsen, W. Wang, and R. L. Martuza
Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.
Clin. Cancer Res., May 1, 2006; 12(9): 2919 - 2927.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. W. van Deventer, W. O'Connor Jr., W. J. Brickey, R. M. Aris, J. P.Y. Ting, and J. S. Serody
C-C Chemokine Receptor 5 on Stromal Cells Promotes Pulmonary Metastasis
Cancer Res., April 15, 2005; 65(8): 3374 - 3379.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Zhang, X. Yang, M. Pins, B. Javonovic, T. Kuzel, S.-J. Kim, L. V. Parijs, N. M. Greenberg, V. Liu, Y. Guo, et al.
Adoptive Transfer of Tumor-Reactive Transforming Growth Factor-{beta}-Insensitive CD8+ T Cells: Eradication of Autologous Mouse Prostate Cancer
Cancer Res., March 1, 2005; 65(5): 1761 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 CROBMHome page
S.S. Prime, M. Davies, M. Pring, and I.C. Paterson
THE ROLE OF TGF-{beta} IN EPITHELIAL MALIGNANCY AND ITS RELEVANCE TO THE PATHOGENESIS OF ORAL CANCER (PART II)
Critical Reviews in Oral Biology & Medicine, November 1, 2004; 15(6): 337 - 347.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. L. Kopp, P. J. Wilder, M. Desler, J.-H. Kim, J. Hou, T. Nowling, and A. Rizzino
Unique and Selective Effects of Five Ets Family Members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the Promoter of the Type II Transforming Growth Factor-{beta} Receptor Gene
J. Biol. Chem., May 7, 2004; 279(19): 19407 - 19420.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. T. Bolick, M. E. Hatley, S. Srinivasan, C. C. Hedrick, and J. L. Nadler
Lisofylline, a Novel Antiinflammatory Compound, Protects Mesangial Cells from Hyperglycemia- and Angiotensin II-Mediated Extracellular Matrix Deposition
Endocrinology, December 1, 2003; 144(12): 5227 - 5231.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shah, A. H.
Right arrow Articles by Lee, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, A. H.
Right arrow Articles by Lee, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online